Do analysts rate CNTN or CNNE?

Cannae has a consensus target price of $16.50, suggesting a potential upside of 6.04%. Given Cannae's stronger consensus rating and higher possible upside, analysts clearly believe Cannae is more favorable than Hillstream Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cannae 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Do analysts prefer CNTN or ACTG?

Acacia Research has a consensus target price of $6.00, indicating a potential upside of 35.14%. Given Acacia Research's stronger consensus rating and higher possible upside, analysts plainly believe Acacia Research is more favorable than Hillstream Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Acacia Research 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts recommend FWDI or CNTN?

Forward Industries presently has a consensus target price of $7.50, suggesting a potential upside of 18.30%. Given Forward Industries' stronger consensus rating and higher possible upside, research analysts plainly believe Forward Industries is more favorable than Hillstream Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Forward Industries 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend CEPO or CNTN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cantor Equity Partners 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, CEPO or CNTN?

Cantor Equity Partners is trading at a lower price-to-earnings ratio than Hillstream Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cantor Equity Partners N/A N/A -$6.66M -$0.29 N/A Hillstream Biopharma N/A N/A -$35.92M -$0.50 N/A

Is CEPO or CNTN more profitable?

Cantor Equity Partners' return on equity of 0.00% beat Hillstream Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Cantor Equity Partners N/A N/A -0.74% Hillstream Biopharma N/A -20.06% -15.90%

Do analysts prefer CNTN or MAAS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Maase 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, CNTN or MAAS?

Maase has higher revenue and earnings than Hillstream Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hillstream Biopharma N/A N/A -$35.92M -$0.50 N/A Maase $109.05M 2.38 -$27.36M N/A N/A

Is CNTN or MAAS more profitable?

Maase's return on equity of 0.00% beat Hillstream Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Hillstream Biopharma N/A -20.06% -15.90% Maase N/A N/A N/A

Hillstream Biopharma (CNTN) Competitors

$2.28 +0.06 (+2.70%)

As of 08/31/2026 04:00 PM Eastern

Compare

CNTN vs. CNNE, ACTG, FWDI, CEPO, and MAAS

Should you buy Hillstream Biopharma stock or one of its competitors? Hillstream Biopharma's main competitors and comparable companies include Cannae (CNNE), Acacia Research (ACTG), Forward Industries (FWDI), Cantor Equity Partners (CEPO), and Maase (MAAS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "multi-sector holdings" industry.

How does Hillstream Biopharma compare to Cannae?

Hillstream Biopharma (NASDAQ:CNTN) and Cannae (NYSE:CNNE) are both small-cap finance companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership.

1.2% of Hillstream Biopharma shares are held by institutional investors. Comparatively, 88.1% of Cannae shares are held by institutional investors. 3.3% of Hillstream Biopharma shares are held by insiders. Comparatively, 10.9% of Cannae shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Cannae had 6 more articles in the media than Hillstream Biopharma. MarketBeat recorded 7 mentions for Cannae and 1 mentions for Hillstream Biopharma. Hillstream Biopharma's average media sentiment score of 1.87 beat Cannae's score of 1.75 indicating that Hillstream Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Hillstream Biopharma	Very Positive
Cannae	Very Positive

Hillstream Biopharma has a net margin of 0.00% compared to Cannae's net margin of -38.18%. Cannae's return on equity of -14.10% beat Hillstream Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hillstream Biopharma	N/A	-20.06%	-15.90%
Cannae	-38.18%	-14.10%	-10.60%

Hillstream Biopharma has a beta of 1.45, meaning that its stock price is 45% more volatile than the broader market. Comparatively, Cannae has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market.

Hillstream Biopharma has higher earnings, but lower revenue than Cannae. Cannae is trading at a lower price-to-earnings ratio than Hillstream Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hillstream Biopharma	N/A	N/A	-$35.92M	-$0.50	N/A
Cannae	$423.60M	1.59	-$513.20M	-$3.02	N/A

Cannae has a consensus target price of $16.50, suggesting a potential upside of 6.04%. Given Cannae's stronger consensus rating and higher possible upside, analysts clearly believe Cannae is more favorable than Hillstream Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cannae	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Cannae beats Hillstream Biopharma on 9 of the 15 factors compared between the two stocks.

How does Hillstream Biopharma compare to Acacia Research?

Hillstream Biopharma (NASDAQ:CNTN) and Acacia Research (NASDAQ:ACTG) are both small-cap finance companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

Hillstream Biopharma has a beta of 1.45, indicating that its share price is 45% more volatile than the broader market. Comparatively, Acacia Research has a beta of 0.45, indicating that its share price is 55% less volatile than the broader market.

1.2% of Hillstream Biopharma shares are owned by institutional investors. Comparatively, 86.7% of Acacia Research shares are owned by institutional investors. 3.3% of Hillstream Biopharma shares are owned by company insiders. Comparatively, 1.7% of Acacia Research shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Acacia Research has a consensus target price of $6.00, indicating a potential upside of 35.14%. Given Acacia Research's stronger consensus rating and higher possible upside, analysts plainly believe Acacia Research is more favorable than Hillstream Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Acacia Research	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Hillstream Biopharma and Hillstream Biopharma both had 1 articles in the media. Hillstream Biopharma's average media sentiment score of 1.87 equaled Acacia Research'saverage media sentiment score.

Company	Overall Sentiment
Hillstream Biopharma	Very Positive
Acacia Research	Very Positive

Acacia Research has higher revenue and earnings than Hillstream Biopharma. Acacia Research is trading at a lower price-to-earnings ratio than Hillstream Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hillstream Biopharma	N/A	N/A	-$35.92M	-$0.50	N/A
Acacia Research	$285.23M	1.52	$21.68M	-$0.15	N/A

Hillstream Biopharma has a net margin of 0.00% compared to Acacia Research's net margin of -5.39%. Acacia Research's return on equity of 0.44% beat Hillstream Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hillstream Biopharma	N/A	-20.06%	-15.90%
Acacia Research	-5.39%	0.44%	0.33%

Summary

Acacia Research beats Hillstream Biopharma on 9 of the 13 factors compared between the two stocks.

How does Hillstream Biopharma compare to Forward Industries?

Forward Industries (NASDAQ:FWDI) and Hillstream Biopharma (NASDAQ:CNTN) are both small-cap finance companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

Forward Industries presently has a consensus target price of $7.50, suggesting a potential upside of 18.30%. Given Forward Industries' stronger consensus rating and higher possible upside, research analysts plainly believe Forward Industries is more favorable than Hillstream Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forward Industries	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Forward Industries has a beta of 0.81, indicating that its stock price is 19% less volatile than the broader market. Comparatively, Hillstream Biopharma has a beta of 1.45, indicating that its stock price is 45% more volatile than the broader market.

In the previous week, Forward Industries had 2 more articles in the media than Hillstream Biopharma. MarketBeat recorded 3 mentions for Forward Industries and 1 mentions for Hillstream Biopharma. Hillstream Biopharma's average media sentiment score of 1.87 beat Forward Industries' score of 0.76 indicating that Hillstream Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Forward Industries	Positive
Hillstream Biopharma	Very Positive

Hillstream Biopharma has a net margin of 0.00% compared to Forward Industries' net margin of -2,073.82%. Forward Industries' return on equity of -18.05% beat Hillstream Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forward Industries	-2,073.82%	-18.05%	-17.03%
Hillstream Biopharma	N/A	-20.06%	-15.90%

1.2% of Hillstream Biopharma shares are owned by institutional investors. 15.9% of Forward Industries shares are owned by insiders. Comparatively, 3.3% of Hillstream Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Hillstream Biopharma has lower revenue, but higher earnings than Forward Industries. Hillstream Biopharma is trading at a lower price-to-earnings ratio than Forward Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forward Industries	$18.19M	25.74	-$166.97M	$0.12	52.83
Hillstream Biopharma	N/A	N/A	-$35.92M	-$0.50	N/A

Summary

Forward Industries beats Hillstream Biopharma on 9 of the 15 factors compared between the two stocks.

How does Hillstream Biopharma compare to Cantor Equity Partners?

Cantor Equity Partners (NASDAQ:CEPO) and Hillstream Biopharma (NASDAQ:CNTN) are both small-cap finance companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, risk and earnings.

Cantor Equity Partners is trading at a lower price-to-earnings ratio than Hillstream Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cantor Equity Partners	N/A	N/A	-$6.66M	-$0.29	N/A
Hillstream Biopharma	N/A	N/A	-$35.92M	-$0.50	N/A

Cantor Equity Partners has a beta of -0.05, meaning that its stock price is 105% less volatile than the broader market. Comparatively, Hillstream Biopharma has a beta of 1.45, meaning that its stock price is 45% more volatile than the broader market.

In the previous week, Cantor Equity Partners had 1 more articles in the media than Hillstream Biopharma. MarketBeat recorded 2 mentions for Cantor Equity Partners and 1 mentions for Hillstream Biopharma. Hillstream Biopharma's average media sentiment score of 1.87 beat Cantor Equity Partners' score of 0.43 indicating that Hillstream Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Cantor Equity Partners	Neutral
Hillstream Biopharma	Very Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cantor Equity Partners	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cantor Equity Partners' return on equity of 0.00% beat Hillstream Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cantor Equity Partners	N/A	N/A	-0.74%
Hillstream Biopharma	N/A	-20.06%	-15.90%

1.2% of Hillstream Biopharma shares are held by institutional investors. 3.3% of Hillstream Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Cantor Equity Partners and Hillstream Biopharma tied by winning 5 of the 10 factors compared between the two stocks.

How does Hillstream Biopharma compare to Maase?

Hillstream Biopharma (NASDAQ:CNTN) and Maase (NASDAQ:MAAS) are both small-cap finance companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

1.2% of Hillstream Biopharma shares are held by institutional investors. 3.3% of Hillstream Biopharma shares are held by insiders. Comparatively, 87.6% of Maase shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Maase's return on equity of 0.00% beat Hillstream Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hillstream Biopharma	N/A	-20.06%	-15.90%
Maase	N/A	N/A	N/A

Maase has higher revenue and earnings than Hillstream Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hillstream Biopharma	N/A	N/A	-$35.92M	-$0.50	N/A
Maase	$109.05M	2.38	-$27.36M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Maase	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Hillstream Biopharma has a beta of 1.45, suggesting that its share price is 45% more volatile than the broader market. Comparatively, Maase has a beta of 0.02, suggesting that its share price is 98% less volatile than the broader market.

In the previous week, Maase had 1 more articles in the media than Hillstream Biopharma. MarketBeat recorded 2 mentions for Maase and 1 mentions for Hillstream Biopharma. Hillstream Biopharma's average media sentiment score of 1.87 beat Maase's score of 0.94 indicating that Hillstream Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Hillstream Biopharma	Very Positive
Maase	Positive

Summary

Maase beats Hillstream Biopharma on 6 of the 9 factors compared between the two stocks.

Get Hillstream Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CNTN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CNTN vs. The Competition

Export

Metric	Hillstream Biopharma	Financial Services Industry	Finance Sector	NASDAQ Exchange
Market Cap	$176.89M	$27.29B	$14.04B	$12.89B
Dividend Yield	N/A	6.06%	5.88%	11.27%
P/E Ratio	-4.56	19.63	26.68	25.48
Price / Sales	N/A	453.01	520.92	97.10
Price / Cash	N/A	49.15	30.40	36.03
Price / Book	0.21	3.25	2.78	6.34
Net Income	-$35.92M	$1.10B	$1.31B	$349.45M
7 Day Performance	-1.30%	-0.81%	-0.25%	-0.65%
1 Month Performance	18.13%	12.55%	2.52%	4.48%
1 Year Performance	N/A	-1.72%	10.56%	14.89%

Hillstream Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CNTN Hillstream Biopharma	0.6543 of 5 stars	$2.28 +2.7%	N/A	N/A	$176.89M	N/A	N/A	2
CNNE Cannae	1.7998 of 5 stars	$15.61 +1.4%	$16.50 +5.7%	-16.6%	$667.53M	$423.60M	N/A	6,602
ACTG Acacia Research	2.5725 of 5 stars	$4.50 -0.2%	$6.00 +33.3%	+30.2%	$440.12M	$285.23M	N/A	1,036	Positive News
FWDI Forward Industries	2.0778 of 5 stars	$6.05 +5.6%	$7.50 +24.0%	N/A	$423.14M	$18.19M	50.42	100	High Trading Volume
CEPO Cantor Equity Partners	0.2729 of 5 stars	$10.78 -0.2%	N/A	+2.8%	$275.40M	N/A	N/A	2	Short Interest Increase High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CNTN) was last updated on 9/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Hillstream Biopharma (CNTN) Competitors

CNTN vs. CNNE, ACTG, FWDI, CEPO, and MAAS

How does Hillstream Biopharma compare to Cannae?

Summary

How does Hillstream Biopharma compare to Acacia Research?

Summary

How does Hillstream Biopharma compare to Forward Industries?

Summary

How does Hillstream Biopharma compare to Cantor Equity Partners?

Summary

How does Hillstream Biopharma compare to Maase?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTN vs. The Competition

Hillstream Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Hillstream Biopharma (CNTN) Competitors

CNTN vs. CNNE, ACTG, FWDI, CEPO, and MAAS

How does Hillstream Biopharma compare to Cannae?

Do insiders and institutionals have more ownership in CNTN or CNNE?

Does the media favor CNTN or CNNE?

Is CNTN or CNNE more profitable?

Which has more risk and volatility, CNTN or CNNE?

Which has higher valuation and earnings, CNTN or CNNE?

Do analysts rate CNTN or CNNE?

Summary

How does Hillstream Biopharma compare to Acacia Research?

Which has more risk and volatility, CNTN or ACTG?

Do insiders & institutionals believe in CNTN or ACTG?

Do analysts prefer CNTN or ACTG?

Does the media favor CNTN or ACTG?

Which has preferable earnings & valuation, CNTN or ACTG?

Is CNTN or ACTG more profitable?

Summary

How does Hillstream Biopharma compare to Forward Industries?

Do analysts recommend FWDI or CNTN?

Which has more volatility and risk, FWDI or CNTN?

Does the media refer more to FWDI or CNTN?

Is FWDI or CNTN more profitable?

Do insiders & institutionals hold more shares of FWDI or CNTN?

Which has preferable valuation and earnings, FWDI or CNTN?

Summary

How does Hillstream Biopharma compare to Cantor Equity Partners?

Which has stronger earnings and valuation, CEPO or CNTN?

Which has more risk & volatility, CEPO or CNTN?

Does the media favor CEPO or CNTN?

Do analysts recommend CEPO or CNTN?

Is CEPO or CNTN more profitable?

Do institutionals and insiders have more ownership in CEPO or CNTN?

Summary

How does Hillstream Biopharma compare to Maase?

Do insiders and institutionals believe in CNTN or MAAS?

Is CNTN or MAAS more profitable?

Which has higher valuation & earnings, CNTN or MAAS?

Do analysts prefer CNTN or MAAS?

Which has more risk & volatility, CNTN or MAAS?

Does the media prefer CNTN or MAAS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTN vs. The Competition

Hillstream Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools